Please login to the form below

Not currently logged in

Christine Placet appointed CEO of Trophos

Will lead company as it seeks partners for drugs in cardiology and neurology

Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron.

Placet had served as chief financial officer at the French clinical stage pharma company since 2004, and takes up her new role immediately.

According to Trophos, the promotion is part of an internal succession plan designed to provide continuity for the company as it looks to conclude ongoing development programmes and find partnerships for its advance clinical development drug candidates.

These comprise olesoxime for spinal muscular atrophy (SMA) and multiple sclerosis (MS) disease progression, and TRO40303 for cardiac ischemia-reperfusion injury (IRI) – damage caused by the reintroduction of blood supply to tissues after a previous restriction.

"There is considerable market potential of nearly $2bn for the conditions targeted by our pipeline,” said Placet.

“As importantly, we will look to continue to bring hope to patients with the serious and under-treated conditions that we specialise in."

Prior to joining Trophos in 2004, Placet served as chief financial officer in several companies across various industries.

She was also an auditor at Ernst & Young for eight years.

15th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Australian Flu and the dilemma of naming diseases
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....